Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine

KAI WANG, NHI HUYNH, XIAO WANG, GRAHAM BALDWIN, MEHRDAD NIKFARJAM and HONG HE

Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia

Received August 11, 2017; Accepted October 18, 2017

DOI: 10.3892/ijo.2017.4193

Abstract. Pancreatic ductal adenocarcinoma (PDA) is one of the major types of cancer that exhibit high mortality worldwide because of the late diagnosis and the lack of effective treatment. Immunotherapy appears to be ineffective in PDA treatment due to the existence of a unique immune-suppressive microenvironment in PDA. Gemcitabine-based therapy is still the most commonly used chemotherapy to treat PDA patients with only marginal increased survival rates. This prompted us to continue the search for more effective therapy for PDA treatment. The effects of p21 activated kinases (PAKs) on tumour immune response and gemcitabine response were examined in PDA. An orthotopic murine PDA model, in which pancreatic cancer cells were injected to the tail of pancreas, was used. The mice were treated with PAK inhibitor, PF-3758309, plus or minus gemcitabine. Tumour growth was measured by volume and weight. Tumour immune response was determined by flow cytometry analysis of splenic cells and immunohistochemical staining of intratumoural lymphocytes. Inhibition of PAKs by PF-3758309, not only suppressed tumour growth, but also stimulated tumour immune response by increasing the numbers of splenic and intratumoural T lymphocytes. Furthermore, inhibition of PAKs decreased PDA cell growth synergistically with gemcitabine in vitro and in vivo. The dual effects of inhibition of PAKs make PAK-targeted therapy more potent for the treatment of PDA. The combination of PAK inhibitors with gemcitabine may be a more effective therapeutic approach in PDA treatment.

Introduction

Pancreatic cancer is an aggressive and lethal malignancy with an overall 5-year survival rate <8%, and its death rate continues to increase by 0.3% per annum (1). Although surgery remains a potentially curative treatment, chemotherapy is an important and indispensable therapy in maximizing the life span for patients with both resectable and unresectable tumours. Currently, gemcitabine-based therapies, either alone or in combination with agents as such nab-paclitaxel (2), are favored approaches for treatment of patients with locally advanced or metastatic pancreatic cancer. Although the regimen, folic acid, 5-fluorouracil, irinotecan, oxalaplatin (FOLFIRINOX), has increased survival compared to gemcitabine, it often cannot be tolerated due to its high toxicity and the poor performance status of patients (3). This necessitates a continued search for more effective and less toxic combination therapies for the treatment of pancreatic cancer.

Immunotherapy to activate antitumour immunity has delivered promising results in various tumours (4). However, immunotherapy has little effect in pancreatic ductal adenocarcinoma (PDA) because of the potently immunosuppressive microenvironment in which immune cells, PDA cells and stroma interact to facilitate cancer progression (5). A combination approach involving chemotherapy, immunotherapy, targeted therapy against stromal elements, and other modalities, may be required in order to stimulate antitumour immunity, increase treatment efficacy and improve survival.

The p21 activated kinase (PAK) family of serine/threonine kinases, the downstream effector proteins of Rho GTPases, are categorized into two groups. Both group I (PAK1-3) and group II (PAK4-6) PAKs are involved in multiple cellular signaling pathways that regulate cell survival, proliferation, and migration (6). Overexpression and hyper-activation of PAKs contribute significantly to the initiation and progression of human cancers, and PAK1 and PAK4 are the best-studied members in this area. PAK1 expression is upregulated in both human pancreatic cancer cells and tissues (7). Inhibition of PAK1 in pancreatic cancer cell lines by shRNA knock-down or a PAK1 specific inhibitor (Frax-597) decreased cancer cell growth, synergistically with gemcitabine (7). PAK4 upregulation enhanced pancreatic cancer cell proliferation and survival through AKT- and ERK-dependent activation of the NF-κB pathway (8), and stimulated migration and invasiveness. In addition, PAK4 has been linked to the maintenance of a...
Kras mutations have been observed in >95% of PDA (11). The failure to identify a drug-binding domain in the Kras protein has made it difficult to be targeted therapeutically. Therefore, the ability to target other downstream molecules in Kras signaling pathways has become increasingly important. PAK1 can be activated via a Ras-dependent pathway and at least in part, mediates the effect of activated Kras in pancreatic cancer (6). In this study, a PAK inhibitor [PF-3758309, IC50, 13.7 nM for PAK1 and 1.3 nM for PAK4 (12)] was used to evaluate the combined effect of PAK inhibition with gemcitabine on pancreatic cancer growth and on the tumour immune response.

Materials and methods

Cells and reagents. Human PANC-1 and MiaPaCa-2 pancreatic cancer cells (purchased from Sigma-Aldrich, Melbourne, Australia) and a murine PANO2 pancreatic cancer cell line obtained from National Cancer Institute (Frederick, MD, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% FBS (fetal bovine serum; Hyclone Laboratories Inc., Melbourne, Australia) in a 37°C incubator with a humidified atmosphere of 5% CO2. PF-3758309 was purchased from Active Biochemical Co., Maplewood, NJ, USA and gemcitabine from Sigma-Aldrich. PAK1 knock-down (KD) PANC-1 and MiaPaCa-2 cells were generated by transfection with SureSilencing shRNA plasmids for human PAK1 (SABioscience, Doncaster, Australia), or with a scrambled sequence as a negative control, using Lipofectamine 2000 (Invitrogen, Mulgrave, Australia), according to the manufacturer's instructions. Stable clones were selected with geneticin (G418; 1 mg/ml). PAK protein expression was detected by western blotting.

Cell proliferation. Cell proliferation was measured using a 3H-thymidine incorporation assay. Cells (5x103 cells/well) were seeded in a 96-well plate and incubated in DMEM containing 5% FBS, with 1 µCi/well [methyl-3H]-thymidine (Perkin-Elmer, Boston, MA, USA) in the presence of PF-3758309 at the concentrations indicated in the Results section. After 24 h, cells were harvested using a NUNC cell harvester (Nunc, Roskilde, Denmark). The amount of 3H-thymidine incorporated through DNA synthesis was detected with a β-counter (Packard, Meriden, CT, USA). For combinational treatment, cells were pre-treated with PF-3758309 for 24 h, and then PF-3758309 was removed. The cells were incubated with increasing concentrations of gemcitabine and 1 µCi/well [methyl-3H]-thymidine for a further 24 h and harvested and detected as above.

Migration/invasion assay. Cell migration/invasion was measured using a Transwell Boyden Chamber assay as described previously (13). Membranes (8-µm pore size; Becton-Dickinson, NJ, USA) were coated with 3 µg of human fibronectin on the lower surfaces and placed into a 24-well plate containing 600 µl/well of serum-free DMEM with 0.1% bovine serum albumin (BSA). Cells were added to the upper chambers at 5x104/100 µl with or without PF-3758309 at the concentrations indicated. Cells were then incubated for 24 h. Cells that had not penetrated were removed from the upper surface by wiping with a cotton swab. The membranes were then fixed and stained with Quick-Dip (Fronine, Sydney, Australia). The cells that had migrated to the lower surface of the membranes were counted in 24-48 fields, depending on the cell line, at x4 magnification using a Nikon Coolscope (Coherent Scientific, Adelaide, Australia). The combined effects of gemcitabine and PF-3758309 were evaluated using the Chou-Talalay method as previously described (14). The combination index (CI) was calculated with the CalcuSyn program (T.C. Chou and M.P. Hayball; Biosoft, Cambridge, UK) using the mutually non-exclusive (α=1) isobologram equation. The CI value is interpreted as follows: <1.0, synergistic; 1.0, additive and >1.0, antagonistic.

Anchorage-independent assay. Anchorage-independent growth of pancreatic cancer cell lines was determined by soft agar assay as described previously (15). Briefly, cells (2,000/well) were seeded in top agar layer containing 0.4% bacto-agar/DMEM (0.5 ml) over a bottom agar layer of 0.6% bacto-agar/DMEM (1 ml) in 12-well plates. Both layers of soft agar were allowed to set at room temperature for 20-30 min before 0.5 ml of DMEM containing treatment reagents was added to the wells. For wild-type MiaPaCa-2 and PANC-1 cells were divided into four groups: control, PF-3758309, gemcitabine, and combination of PF-3758309 with gemcitabine. For PAK1 knock-down MiaPaCa-2 and PANC-1, each cell line was divided into two groups: control and gemcitabine. The concentrations of PF-3758309 and gemcitabine were chosen close to the IC50 values from the proliferation assay. Cell colonies were grown in a humidified 5% CO2 incubator at 37°C for 4 weeks. Culture medium containing treatment reagents was changed twice weekly. At the endpoint, colonies were fixed and stained with 4% formalin and 0.005% crystal violet in phosphate-buffered saline (PBS). Colonies were counted manually and images were captured using a Leica microscope at x4 magnification.

Animal experiments. All mouse experiments were approved by the Austin Health Research Ethics Committee (A2013/04898). An orthotopic pancreatic cancer tail model was used to assess tumour growth in the pancreatic tails of C57BL/6 mice as previously described (16). PANO2 (a murine pancreatic cancer cell line) cells were injected into the pancreatic tails of 24 PAK1 wild-type (WT) mice, which were allocated randomly into four treatment groups (6 mice/group): control, intraperitoneal (i.p.) injection of saline every other day; gemcitabine (40 mg/kg), i.p. twice weekly; PF-3758309 (25 mg/kg), i.p. every other day; combination of gemcitabine with PF-3758309, following the individual treatment as described above. For assessment of tumour growth in PAK1 knockout (KO) C57BL/6 mice, 9 mice were injected with PANO2 cells in the pancreatic tail and were allocated randomly into two groups: control (n=4) and gemcitabine (n=5), and treated as described above. All treatments commenced one week after surgical induction and continued for 4 weeks. All mice were monitored based on strict health monitoring criteria and euthanized when a poor health score was reached. At the endpoint, tumour dimensions were measured using micro-calipers. The tumour volume was
calculated by using the formula: \( V = L \times W \times H \times \left(\pi/6\right) \), where \( L \) was the length; \( W \) the width; and \( H \) the height.

**Flow cytometric analysis.** Spleens were harvested from tumour-bearing mice as described above, and homogenised in 0.5% BSA in PBS. The splenic cells were collected by centrifugation after red cells had been removed using red cell lysis buffer (150 mM \( \text{Na}_4\text{Cl} \), 10 mM \( \text{Na}_2\text{HCO}_3 \), 0.1 mM \( \text{EDTA} \)). After further washing in 0.5% BSA in PBS, the remaining cells were incubated for 1 h on ice with FITC- or APC-labelled antibodies against B220, CD3, CD8 (1:100) (BD Biosciences, North Ryde, Australia) or Cd4 (1:10) (Miltenyi Biotec, Macquarie Park, Australia), or with respective isotype controls. Cells were washed 3 times in 0.5% BSA in PBS before analysis by FACSCanto II (BD Biosciences). Data were analysed using Weasel software (Cytometry Laboratory, Walter and Eliza Hall Institute, Parkville, Australia).

**Immunohistochemistry stain.** Tumour tissues, collected from the orthotopic tail model as described above, were embedded in paraffin and stained with Ki67 antibody (Thermo Fisher Scientific, Melbourne, Australia) for proliferation, active caspase 3 antibody (Cell Signaling Technology, Arundel, Australia) for apoptosis, or CD3 antibody (Abcam, Melbourne, Australia) for total T cell surface marker. Samples were imaged using a Leica microscope for at least 4 fields at x40 magnification. For the CD3+ stain, cell numbers were counted per x40 field. For the Ki67 and caspase 3 stains, the ratio of positive cells to total number of cells in each field was calculated.

**Western blotting.** Cells were treated with PF-3758309 at the \( IC_{50} \) concentration for 24 h, lysed in SDS sample buffer, and denatured by heating at 95°C for 5 min. Proteins in the cell lysates were detected with antibodies against phospho-PAK1, PAK1, phospho-PAK4, PAK4 and GAPDH. All primary antibodies were purchased from Cell Signaling Technology. The bound antibodies were visualized using ECL reagents (GE Healthcare, Amersham, UK) and the density of each band was analyzed using Multigauge computer software (Berthold, Bundoora, Australia).

**Statistical analysis.** All values were expressed as mean ± standard error. Results were analyzed by Student’s t-test or one-way ANOVA (SPSS, IBM, New York, NY, USA). Differences between two means with \( p<0.05 \) were considered statistically significant.

**Results**

**PF-3758309 inhibits pancreatic cancer cell proliferation and migration.** Human (MiaPaCa-2 and PANC-1) and murine (PAN02) pancreatic cancer cells were cultured with increasing doses of PF-3758309 (Fig. 1A and B) for 24 h. Cell proliferation and migration/invasion were measured by \( ^{3}\text{H}-\text{thymidine incorporation and Boyden chamber assays,} \)
respectively. PF-3758309 decreased the proliferation and migration/invasion of both human and murine pancreatic cancer cells (Fig. 1A and B) in a dose-dependent manner, the IC₅₀ values are given in Table I. The three pancreatic cancer cell lines were then incubated for 24 h with PF-3758309 at the IC₅₀ concentrations calculated from proliferation assays (Fig. 1A) and the expression of phosphorylated and active PAK1 and PAK4, as well as total PAK1 and PAK4, was measured by western blotting. PF-3758309 inhibited the activity of PAK1 in the three cell lines tested (Fig. 1C), and the activity of PAK4 in MiaPaCa-2 and PAN02. These data indicated that PF-3758309 suppressed pancreatic cancer cell proliferation and migration probably via inhibition of the activities of both PAK1 and PAK4.

**PF-3758309 inhibits pancreatic cancer cell proliferation synergistically with gemcitabine.** The combined effects of PF-3758309 and gemcitabine on proliferation were measured by incubation of the pancreatic cancer cell lines with different concentrations of gemcitabine, alone or in combination with pre-treatment of PF-3758309, at concentrations around the IC₅₀ values given in Table I. Gemcitabine on its own inhibited proliferation in the three pancreatic cancer cell lines in a dose-dependent manner (Fig. 2). A further reduction of proliferation was observed in all three cell lines when the cells were treated with PF-3758309 and gemcitabine in combination, compared to treatment with gemcitabine alone (Fig. 2). The combined effect of PF-3758309 and gemcitabine was shown to be synergistic rather than additive when analysed by the Chou-Talalay method (17) (Fig. 3). These results demonstrated that PF-3758309 and gemcitabine synergistically inhibited pancreatic cancer cell growth.

**Inhibition of PAKs promotes the suppression by gemcitabine of anchorage-independent growth of pancreatic cancer cells.**

<table>
<thead>
<tr>
<th>Table I. The IC₅₀ for inhibition of proliferation and migration/invasion of pancreatic cancer cell lines by PF-3758309.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Concentration</strong></td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Proliferation (nM)</td>
</tr>
<tr>
<td>Migration/invasion (nM)</td>
</tr>
</tbody>
</table>

**Figure 2.** PF-3758309 and gemcitabine synergistically inhibits the proliferation of pancreatic cancer cells. The pancreatic cancer cell lines, MiaPaCa-2 (A), PANC-1 (B) and PAN02 (C) were pre-treated with PF-3758309 at the IC₅₀ concentrations calculated from proliferation (Fig. 1 and Table I) for 24 h. PF-3758309 was then removed, and the cells were treated with gemcitabine (Gem) at 50, 100 and 200 nM for another 24 h. Cell proliferation was measured by [H]-thymidine incorporation. PF-3758309 inhibited the proliferation of all three cell lines tested synergistically with gemcitabine. The data were summarized from three independent experiments. *p<0.05, **p<0.01, compared to the values from cells without any treatment. ***p<0.01, compared to the values from cells treated by either PF-3758309 or gemcitabine alone.

**Figure 3.** PF-3758309 inhibits pancreatic cancer cell proliferation synergistically with gemcitabine. The pancreatic cancer cell lines MiaPaCa-2, PANC-1 (human) and PAN02 (murine) were pre-treated with PF-3758309 at the IC₅₀ concentrations given in Table I for 24 h followed by incubation with the concentrations of gemcitabine indicated in Fig. 2 for another 24 h. Cell proliferation was measured by [H]-thymidine incorporation. The combined effects of gemcitabine and PF-3758309 were evaluated by calculating the combination index (CI) using the mutually non-exclusive (α=1) isobologram equation. The CI value is interpreted as follows: <1.0, synergistic; 1.0, additive and >1.0, antagonistic.
The combined effect of inhibition of PAK by PF-3758309 with gemcitabine on anchorage-independent growth of pancreatic cancer cells was measured by growing cells in soft agar, followed by treatment with gemcitabine alone or in combination with PF-3758309 at concentrations around the IC50 values calculated from the proliferation assay. Either PF-3758309 or gemcitabine alone decreased the numbers of colonies formed in the agar in both MiaPaCa-2 and PANC-1 cells (Fig. 4). Combined treatment with PF-3758309 and gemcitabine resulted in a significant further decrease in the numbers of colonies formed compared with either PF-3758309 or gemcitabine alone (Fig. 4). PAN02 did not grow in the soft agar under current condition.

In order to confirm this result, PAK1 expression was reduced by knockdown (KD) with shRNA (Fig. 5A), and the numbers of colonies formed in PAK1 KD with or without gemcitabine were analysed. Cells transfected with a scrambled shRNA sequence served as a negative control (NC). The number of colonies formed in PAK1 KD cells was significantly reduced compared to NC cells. Gemcitabine treatment...
Further decreased the colony numbers in PANC-1 PAK1 KD cells (Fig. 5B), but not in MiaPaCa-2 PAK1 KD cells (Fig. 5C). Furthermore, large colonies containing >100 cells only formed in untreated NC cells. These data demonstrated that inhibition of PAKs by PF-3758309 or by shRNA knockdown enhanced the suppressive effect of gemcitabine on anchorage-independent growth of pancreatic cancer cells.

**Inhibition of PAKs sensitizes the response of pancreatic cancers to gemcitabine in vivo.** A mouse orthotopic pancreatic cancer model was used to determine the effect of inhibition of PAKs on the response of pancreatic cancers to gemcitabine treatment in vivo. Tumours were induced by injection of pancreatic cancer cells into the tail of the pancreas as previously described (16). The tumour take rate was 100% in both PAK1 wild-type (WT) and PAK1 knockout (KO) C57BL/6 mice. None of the mice died from surgery. In PAK1 WT mice, either PF-3758309 or gemcitabine alone significantly reduced tumour growth by decreasing the tumour volume (Fig. 6A and C) and tumour weight (Fig. 6B), compared to untreated controls. A further reduction in both tumour volume and weight was observed in mice treated with the combination of PF-3758309 and gemcitabine. The tumour volume, but not the tumour weight, was significantly decreased in PAK1 KO mice when compared to PAK1 WT mice. Gemcitabine treatment of PAK1 KO mice caused a further reduction in both tumour volume and tumour weight when compared to the tumours in untreated PAK1 KO mice.

Either PF-3758309 or gemcitabine alone inhibited tumour growth by decreasing cell proliferation as measured by Ki67 immunohistochemistry (Fig. 7A). The proliferation in tumours from PAK1 WT mice treated with either PF-3758309 or gemcitabine was reduced to 60.6% and 60.1% of that in tumours from untreated mice. The combination of PF-3758309 and gemcitabine further reduced the proliferation to 25.9% of the untreated PAK1 WT mice. Importantly, the proliferation in tumours from PAK1 KO mice was also significantly reduced compared to tumours from untreated PAK1 WT mice. Gemcitabine treatment of PAK1 KO mice further decreased cell proliferation in tumours when compared to the corresponding untreated PAK1 KO mice (Fig. 7A). No significant difference was detected in apoptosis in tumours from all six groups although compared to control of PAK1 WT mice, there were increased trend in all other groups of treatment mice (Fig. 7B). These results indicate that inhibition of PAKs by PF-3758309 or by PAK1 knockout sensitized pancreatic cancers to gemcitabine in vivo at least by decreasing cell proliferation.

**Inhibition of PAKs enhances tumour immune response in vivo.** To determine the effect of PAK inhibition on tumour immune response, spleens were dissected from the tumour-bearing mice treated as shown in Fig. 6. The red blood cells were removed, and the splenic cells were extracted and subjected to FACS analysis as described in the Materials and methods. In the PAK1 WT mice, both CD3+ and CD8+ T lymphocytes
were increased by treatment with PF-3758309 alone or in combination with gemcitabine (Fig. 8A). Both CD3+ and CD8+ T lymphocytes were increased in untreated PAK1 KO mice compared to untreated PAK1 WT mice. Gemcitabine treatment did not cause any significant changes in CD3+ or CD8+ T lymphocytes of either PAK1 WT or PAK1 KO mice (Fig. 8A).
CD3+ T lymphocytes were stained in pancreatic tumour tissues from all 6 groups of mice to determine the tumour-infiltrating immune cells. In the tumours in PK1 WT mice, CD3+ T lymphocytes were increased by treatment with PF-3758309 alone or in combination with gemcitabine (Fig. 8B). CD3+ T lymphocytes were also increased in tumours in untreated PK1 KO mice compared to tumours in untreated PK1 WT mice. Gemcitabine treatment alone did not cause any significant changes in CD3+ T lymphocytes in tumours from either PK1 WT or PK1 KO mice (Fig. 8B). These results indicate that inhibition of PAKs by PF-3758309 or by PK1 KO upregulated the immune response of tumour-bearing mice by stimulation of both splenic CD3+ and CD8+ T lymphocytes and tumour-infiltrating CD3+ T lymphocytes.

Discussion

Our most important findings in this study are that, in an orthotopic pancreatic cancer mouse model, inhibition of PK1 and PK4 by PF-3758309 or depletion of PK1 not only suppressed the growth of pancreatic cancer in vivo, but also stimulated the immune response by increasing the numbers of splenic CD3+ and CD8+ T lymphocytes as well as by enhancing the tumour-infiltrating CD3+ T lymphocytes. Tumour-infiltrating leukocytes (TILs) are critical determinants of clinical outcome of cancer patients, and play key roles in cancer progression and in therapeutic responses (18-20). Among TILs, the activation and location of T lymphocytes are particularly important. The location and density of intratumoural CD8+ T lymphocytes alters their prognostic significance (21). Infiltration of CD3+ T lymphocytes is associated with a significantly higher rate of progression-free survival of gastrointestinal cancer patients (22). In PDA patients, the presence of both CD4+ and CD8+ T lymphocytes in tumour tissues correlated with an improved prognosis and increased 5-year survival rate (23-25). These pieces of evidence stimulated the initiation and development of immune-therapeutic approaches to enhance the antitumour immune response through regulation of TILs. Our finding that inhibition of PK1 and PK4 by PF-3758309 or depletion of PK1 increased the number of the tumour infiltrating CD3+ T lymphocytes in an orthotopic pancreatic cancer mouse model indicates the potential role of PAK inhibitors in modulation of TILs in order to improve antitumour immunity. Our finding also prompted us to further investigate the role of PAKs in tumour immune response and tumour microenvironment using KPC mouse (KrasG12D+/+; Trp53R172H/+; Pdx-1-Cre) which incorporates expression of KrasG12D+ and Trp53R172H+ alleles targeted to the mouse pancreas by Cre recombinase under the control of the pancreas-specific Pdx-1 promoter and reproduces key features of human PDA (26).

Gemcitabine, as the base-line therapeutic agent for pancreatic cancer, has been reported to reduce the number of immunosuppressive T regulatory cells (Treg) and myeloid-derived suppressor cells (MDSC), while restoring the ratio of T effector cells to Treg in the blood of pancreatic cancer patients (27). When comparing the number of intratumoural immune cells from patients undertaking gemcitabine treatment to the non-treated controls, gemcitabine did not change the number of intratumoural CD3+ T lymphocytes, but increased the ratios of CD3+/Treg and CD4+/Treg, possibly by reducing the number of FOXP3+ cells (28). In agreement with these clinical observations in patients, in our orthotopic pancreatic cancer model in mice, gemcitabine on its own did not change the number of either splenic CD3+ or CD8+ T lymphocytes or of intratumoural CD3+ T lymphocytes (Fig. 8). The effect of gemcitabine on Treg and MDSC in our model remains to be determined.

Although targeted therapies and immunotherapy have significantly improved the outcome of many solid malignancies such as melanoma and lung cancer, no such effective therapy has been developed for PDA, despite the knowledge of key mutations and an increasing understanding of the tumour microenvironment. Current treatment options for PDA mainly involve combination cytotoxic chemotherapies, which provide a marginal survival benefit at the cost of significant toxicity. Gemcitabine-based treatment is still most commonly applied to pancreatic cancer patients because of its general good patient tolerability and lack of better alternative less toxic combinations of chemotherapies (29). Indeed the combination of targeted therapies of gemcitabine, combined with agents, such as cetuximab or bevacizumab, has not added any additional benefit (30,31).

Consistent with previous reports, we have shown that inhibition of both PK1 and PK4 by PF-3758309 suppressed the growth and migration/invasion of pancreatic cancer cells. Although the Boyden chamber assay is recognised as a standard method to measure cell migration/invasion (in the case of cancer cells). The measurement of MMP-2 and MMP-9 will certainly strengthen our data here, which will be added in our future study. Further we have demonstrated that PF-3758309, either on its own or synergistically with gemcitabine, reduced the growth of pancreatic cancer both in vitro and in vivo. The inhibitory effect of PF-3758309 on three cell lines tested seems to be correlated well with the activity of PK1 as MiaPaCa-2 with lowest level of active phosphorylated PK1 (pPAK1) responded to PF-3758309 most sensitively while PAN02 with highest level of pPAK1 responded to PF-3758309 least sensitively (Fig. 1 and Table 1). That the inhibitory effect of PF-3758309 is mainly mediated by a PK1-dependent pathway is clearly demonstrated by our in vivo observation in the orthotopic pancreatic cancer model that tumour growth was inhibited by PF-3758309 in PK1 wild-type mice to a similar degree to the tumour growth inhibition by PK1 depletion in PK1 knockout mice (Fig. 6). When determining the hematologic toxicities by full blood count, PF-3758309 and gemcitabine alone or in combination reduced the haemoglobin by 10% while PF-3758309 increased the platelet and neutrophils by 50% and 110%, respectively (data not shown). PF-3758309 and/or gemcitabine did not affect any other hematologic index tested. Our findings that inhibition of PAKs not only suppressed pancreatic cancer growth (both alone and synergistically with gemcitabine), but also upregulated the tumour immune response by increasing the splenic and intratumoural lymphocytes, make PAKs in general, and PK1 in particular, an attractive target(s) in developing effective therapeutic regimen.

In conclusion, our results that inhibition of PK1 and PK4 suppressed pancreatic cancer growth/invasion, stimulated the tumour immune response, and promoted the inhibitory effect of gemcitabine, indicate the potential role of PAKs in the
immune response to pancreatic tumours, and provide a solid base for the development of a combination treatment of PAK targeted therapy with gemcitabine to improve the outcome for PDA patients.

Acknowledgements

The authors would like to thank Professor Mauro S. Sandrin for help in the flow cytometry analysis. This study was supported by grants from the National health and medical Research Council of Australia (1041831, GSB/AS), and the Pancare Foundation (GSB, MN). H.H. was supported by Baldwin trust fund. K.W. was supported by Melbourne International Fee Remission Scholarship (MIFRS), Melbourne International Research Scholarship (MIRS) and Pancare Foundation (Moshe Sambor Scholarship).

References